Viking Therapeutics price target raised to $38 from $32 at Truist

Truist raised the firm’s price target on Viking Therapeutics to $38 from $32 and keeps a Buy rating on the shares. The firm is incrementally positive on the potential differentiation of the company’s VK2735’s on tolerability based on the drug’s tolerability data vs tirzepatide’s tolerability data, the analyst tells investors in a research note. Aggressive dose titration, enabled by good tolerability, may be what’s contributing to VK2735’s weight loss efficacy and could be a point of key differentiation in clinic and commercially, the firm added.